JF
MLTX icon

Jump Financial’s MoonLake Immunotherapeutics MLTX Stock Holding History

Jump Financial’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.55M Buy
336,243
+10,275
+3% +$186K 0.05% 413
2026
Q1 		$6.08M Sell
325,968
-99,591
-23% -$1.65M 0.08% 297
2025
Q4 		$5.61M Buy
+425,559
New +$5.02M 0.07% 345
2024
Q3 		– Sell
-15,900
Closed -$699K – 1938
2024
Q2 		$699K Buy
+15,900
New +$673K 0.01% 978

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jump Financial's MLTX Position: Q2 2026 in Review

Jump Financial increased its MoonLake Immunotherapeutics (MLTX) stake by 3.2% in Q2 2026, buying an estimated $186K and bringing the position to 336,243 shares worth $6.55M. The position accounts for 0.05% of the portfolio, ranked #413.

Jump Financial first reported a position in MLTX in Q2 2024 and has held it in 4 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Jump Financial held 336,243 shares of MoonLake Immunotherapeutics worth $6.55M as of Q2 2026.
  • Jump Financial bought 10,275 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $186K.
  • MoonLake Immunotherapeutics made up 0.05% of Jump Financial's portfolio in Q2 2026, its #413 holding.
  • Jump Financial first reported a position in MoonLake Immunotherapeutics in Q2 2024 and has held it in 4 quarters since.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.